ZA912305B - Novel vaccine - Google Patents

Novel vaccine

Info

Publication number
ZA912305B
ZA912305B ZA912305A ZA912305A ZA912305B ZA 912305 B ZA912305 B ZA 912305B ZA 912305 A ZA912305 A ZA 912305A ZA 912305 A ZA912305 A ZA 912305A ZA 912305 B ZA912305 B ZA 912305B
Authority
ZA
South Africa
Prior art keywords
vhbsag
fragment
antibodies
novel vaccine
variant
Prior art date
Application number
ZA912305A
Other languages
English (en)
Inventor
Howard Christopher Thomas
Christopher Thomas Howard
William Frederick Carman
Frederick Carman William
Original Assignee
Imperial College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College filed Critical Imperial College
Publication of ZA912305B publication Critical patent/ZA912305B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA912305A 1990-03-29 1991-03-27 Novel vaccine ZA912305B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909007024A GB9007024D0 (en) 1990-03-29 1990-03-29 Novel vaccine

Publications (1)

Publication Number Publication Date
ZA912305B true ZA912305B (en) 1992-01-29

Family

ID=10673467

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA912305A ZA912305B (en) 1990-03-29 1991-03-27 Novel vaccine

Country Status (16)

Country Link
US (1) US6099840A (fr)
EP (1) EP0522030B1 (fr)
JP (2) JP2876091B2 (fr)
KR (1) KR100208129B1 (fr)
AT (1) ATE125821T1 (fr)
CA (1) CA2078694C (fr)
DE (1) DE69111801T2 (fr)
DK (1) DK0522030T3 (fr)
ES (1) ES2075440T3 (fr)
GB (1) GB9007024D0 (fr)
GR (1) GR3017804T3 (fr)
IE (1) IE67877B1 (fr)
NZ (1) NZ237611A (fr)
PT (1) PT97159B (fr)
WO (1) WO1991014703A1 (fr)
ZA (1) ZA912305B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565354A (en) * 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
CA2067003A1 (fr) * 1991-04-29 1992-10-30 Peter J. Kniskern Vaccin mutant de variante d'antigene de surface d'hbv
EP0533263A3 (en) * 1991-09-20 1994-06-08 Merck & Co Inc A multivalent hepatitis b virus vaccine
WO1993012815A1 (fr) * 1991-12-27 1993-07-08 Gensci Limited Procede d'obtention d'un antigene de surface recombine de l'hepatite b, antigene et vaccin a base de celui-ci
EP0565794A1 (fr) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction des réponses CTL
EP0835663B1 (fr) 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Vaccins combinés contenant des antigènes de surface du virus de l'Hépatite B et d'autres antigènes
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
US6030616A (en) * 1993-03-24 2000-02-29 Imperial College Of Science, Technology & Medicine Hepatitis B escape mutant specific binding molecules
WO1994021812A2 (fr) * 1993-03-24 1994-09-29 Imperial College Of Science, Technology & Medicine Molecules de liaison specifiques aux mutants liberes par l'hepatite b
US5595739A (en) * 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
GB9401987D0 (en) * 1994-02-02 1994-03-30 Imperial College Modified nucleic acid
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
EP0919568A1 (fr) 1997-12-01 1999-06-02 Sorin Diagnostics S.r.l. Mutants de fuite des antigènes de surface du virus de l'hépatite B
CA2332173A1 (fr) * 1998-06-19 1999-12-23 Government Of The Republic Of Singapore Souche virale d'hepatite b induite par vaccin et ses applications
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
AUPP967999A0 (en) 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
FR2815634B1 (fr) * 2000-10-20 2003-10-31 Biomerieux Sa Anticorps monoclonaux diriges contre des virus de l'hepatite b
EP1806363B1 (fr) * 2004-09-22 2013-09-04 Advanced Life Science Institute, Inc. Méthode de détection de l'antigène s du virus de l'hépatite b
WO2006113528A2 (fr) * 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Procede pour exprimer un antigene de surface de virus de l'hepatite b afin de preparer un vaccin
EP2397856B1 (fr) 2006-03-14 2013-11-13 Oregon Health and Science University Procédés pour détecter une infection de tuberculose à mycobactérie
AU2007293673B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
US8188214B2 (en) 2007-02-28 2012-05-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EP2142211A1 (fr) 2007-05-02 2010-01-13 GlaxoSmithKline Biologicals S.A. Vaccin
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
WO2010099472A2 (fr) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Polypeptides spanx-b et leur utilisation
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
WO2014010890A1 (fr) 2012-07-10 2014-01-16 Green Cross Corporation Composition d'anticorps pour la prévention ou le traitement d'une infection par un virus mutant de l'hépatite b
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
RU2586513C1 (ru) * 2015-04-24 2016-06-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ МУТАНТНОГО ПОВЕРХНОСТНОГО АНТИГЕНА ВИРУСА ГЕПАТИТА В (ВАРИАНТЫ)
RU2603729C2 (ru) * 2015-04-24 2016-11-27 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты)
CN108289940B (zh) 2015-08-03 2023-01-13 美国卫生和人力服务部 Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途

Also Published As

Publication number Publication date
IE67877B1 (en) 1996-05-01
AU7561391A (en) 1991-10-21
ATE125821T1 (de) 1995-08-15
DK0522030T3 (da) 1995-12-27
IE911022A1 (en) 1991-10-09
JP2876091B2 (ja) 1999-03-31
EP0522030A1 (fr) 1993-01-13
JPH11178591A (ja) 1999-07-06
US6099840A (en) 2000-08-08
PT97159B (pt) 1998-07-31
AU642729B2 (en) 1993-10-28
CA2078694A1 (fr) 1991-09-30
WO1991014703A1 (fr) 1991-10-03
DE69111801D1 (de) 1995-09-07
NZ237611A (en) 1994-09-27
CA2078694C (fr) 1998-10-27
JP3049018B2 (ja) 2000-06-05
JPH05505805A (ja) 1993-08-26
GR3017804T3 (en) 1996-01-31
DE69111801T2 (de) 1995-12-14
EP0522030B1 (fr) 1995-08-02
KR100208129B1 (ko) 1999-07-15
PT97159A (pt) 1991-12-31
GB9007024D0 (en) 1990-05-30
ES2075440T3 (es) 1995-10-01

Similar Documents

Publication Publication Date Title
ZA912305B (en) Novel vaccine
MX9603182A (es) Vacuna de hepatitis b.
CA2079912A1 (fr) Epitopes du virus de l'hepatite c
CA2103887A1 (fr) Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
IL102687A0 (en) Method for enhancing immunogenicity
SG47062A1 (en) Synthetic antigens for the detection of antibodies to hepatitis virus
EP0243913A3 (fr) Immunogènes peptidiques de l'hépatite B codés par le gène pre-S, vaccins, produits de diagnostic et vésicules de transport lipidique synthétiques
EP0284587A3 (fr) Antigènes peptides synthétiques pour la détection d'infections de HIV-1
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
AU4439993A (en) HCV peptide antigens and method of determining HCV
EP1326895B8 (fr) Anticorps monoclonaux diriges contre des virus de l'hepatite b
WO2002051865A3 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
AU1146692A (en) Recombinant proteins with the immunoreactivity of hepatitis b virus e antigen (hbeag), a process for the preparation thereof and the use thereof in immunoassays and vaccines
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus